Advantis Medical Imaging Company Profile

Background

Advantis Medical Imaging, established in 2016, is dedicated to enhancing medical imaging by integrating advanced technologies with cloud computing. The company's mission is to make medical image analysis more quantitative, accessible, and automated through AI and cloud technology.

Key Strategic Focus

Advantis specializes in developing web-based medical imaging software, notably Brainance MD™, a neuroimaging platform for brain MRI analysis. This platform supports diffusion tensor imaging (DTI), dynamic susceptibility contrast (DSC) perfusion, and functional MRI (fMRI), aiming to improve the detection efficiency of severe human pathologies such as brain tumors, Alzheimer's, Multiple Sclerosis, and ALS.

Financials and Funding

Advantis has secured over €1.2 million in funding through various rounds:

2016: Pre-Seed funding of €225,000 from VentureFriends and angel investors.

2017: Seed funding of €200,000 from VentureFriends.

2019: Seed investment of €700,000 led by Metavallon VC and business angels.

2020: Grants totaling €1.2 million from EU H2020 and Greek Research Grant/ESPA programs.

These funds have been utilized to accelerate promotional and commercial operations, enhance software services through AI integration, and expand research and development efforts.

Pipeline Development

Advantis's flagship product, Brainance MD™, is a web-based neuroimaging software application enabling the display, review, and processing of brain MRI exams. The company is also developing Advantis Prostate, a platform for prostate MRI analysis, which is CE Marked with FDA clearance in progress.

Technological Platform and Innovation

Advantis's technological platform is distinguished by:

Proprietary Technologies: Brainance MD™, a cloud-based neuroimaging platform accessible via web browsers, offering advanced processing of brain MRI exams.

Scientific Methods: Integration of advanced MRI processing techniques, including DTI, DSC perfusion, and fMRI, into a unified, automated, and intuitive interface.

AI Integration: Research into deep learning methodologies for automated tumor detection and anomaly detection across various organs.

Leadership Team

Paris Ziogkas: Co-Founder and Chief Executive Officer. Experienced in business operations with a focus on SaaS, B2B digital health, and medical devices.

Zoi Giavri: Co-Founder, President, and Chief Product Officer. Experienced medical imaging engineer and inventor of novel brain imaging algorithms.

Dimitris Rozakis: Co-Founder and Chief Technology Officer. Senior software engineer with expertise in cloud technology and SaaS.

Competitor Profile

Market Insights and Dynamics

The global medical imaging software market is projected to grow from €2.5 billion to €4.5 billion by 2024, driven by increasing demand for advanced diagnostic tools and the integration of AI and cloud technologies.

Competitor Analysis

Advantis faces competition from companies such as:

Mirada Medical: Specializes in medical imaging software for oncology, with a focus on image fusion and analysis.

MIM Software: Provides imaging solutions for radiation oncology, nuclear medicine, and neuroimaging.

ImmersiveTouch: Develops virtual reality-based surgical planning and training platforms.

Strategic Collaborations and Partnerships

Advantis has engaged in collaborations to strengthen its market position and innovation capacity, including participation in programs like EIT Health and securing funding from Metavallon VC and other investors.

Operational Insights

Advantis differentiates itself through:

Cloud-Based Accessibility: Offering a zero-footprint, browser-based platform that enhances accessibility and collaboration.

Regulatory Compliance: Achieving CE Mark certification and FDA clearance for its products, ensuring adherence to international standards.

AI Integration: Incorporating AI to automate and enhance diagnostic processes, improving efficiency and accuracy.

Strategic Opportunities and Future Directions

Advantis plans to:

Expand Product Portfolio: Develop imaging solutions for additional organs and pathologies, such as prostate and breast imaging.

Enhance AI Capabilities: Further integrate AI to automate diagnostic processes and improve accuracy.

Global Expansion: Strengthen its presence in the European market and enter the U.S. market, aiming to establish a global network of resellers and partners.